Comparing Kadmon Holdings (KDMN) & Syros Pharmaceuticals (SYRS)

Kadmon Holdings (NYSE: KDMN) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap biopharmaceuticals companies, but which is the better business? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, dividends and earnings.

Earnings and Valuation

This table compares Kadmon Holdings and Syros Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Kadmon Holdings $26.06 million 11.17 -$208.75 million ($1.75) -2.11
Syros Pharmaceuticals $320,000.00 1,015.02 -$47.74 million ($2.01) -6.14

Syros Pharmaceuticals has higher revenue, but lower earnings than Kadmon Holdings. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Kadmon Holdings, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Kadmon Holdings and Syros Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Kadmon Holdings -555.91% N/A -124.91%
Syros Pharmaceuticals N/A -62.01% -55.65%

Analyst Ratings

This is a breakdown of current ratings for Kadmon Holdings and Syros Pharmaceuticals, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kadmon Holdings 1 1 3 0 2.40
Syros Pharmaceuticals 0 1 6 0 2.86

Kadmon Holdings presently has a consensus price target of $9.75, suggesting a potential upside of 163.51%. Syros Pharmaceuticals has a consensus price target of $26.14, suggesting a potential upside of 111.66%. Given Kadmon Holdings’ higher possible upside, analysts plainly believe Kadmon Holdings is more favorable than Syros Pharmaceuticals.

Institutional and Insider Ownership

27.5% of Kadmon Holdings shares are held by institutional investors. Comparatively, 54.2% of Syros Pharmaceuticals shares are held by institutional investors. 8.4% of Kadmon Holdings shares are held by insiders. Comparatively, 33.6% of Syros Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Syros Pharmaceuticals beats Kadmon Holdings on 8 of the 12 factors compared between the two stocks.

About Kadmon Holdings

Kadmon Holdings, Inc. is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of various unmet medical needs. The Company is developing product candidates in a number of indications within autoimmune and fibrotic disease, oncology and genetic diseases. Its product pipeline consists of KD025, Tesevatinib and KD034. The Company’s other products include Ribasphere RibaPak, Ribasphere, Qsymia, Tetrabenazine and Valganciclovir. KD025 is an orally available, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2), a molecular target in multiple autoimmune, fibrotic and neurodegenerative diseases. Tesevatinib is an oral tyrosine kinase inhibitor (TKI) designed to block key molecular drivers of tumor growth, metastases and drug resistance. KD034 is the Company’s portfolio of enhanced formulations of trientine hydrochloride for the treatment of Wilson’s disease.

About Syros Pharmaceuticals

Syros Pharmaceuticals, Inc. is a biopharmaceutical company. The Company offers a gene control platform designed to analyze the unexploited region of deoxyribonucleic acid (DNA) in human disease tissue to identify and drug targets linked to genomically defined patient populations. The Company is focused on developing treatments for cancer and immune-mediated diseases and is building a pipeline of gene control medicines. The Company’s drug programs include SY-1425 (retinoic acid receptor alpha (RARa) agonist) and SY-1365 (cyclin-dependent kinase 7 (CDK7) inhibitor). SY-1425 (tamibarotene) is an oral, potent and selective agonist, or activator, of the transcription factor RARa. SY-1365 is a small molecule inhibitor of the transcriptional kinase known as CDK7. The Company is using its platform to analyze gene expression programs across additional cancers, inflammatory diseases and other diseases to identify optimal points of therapeutic intervention in specific subsets of patients.

Receive News & Ratings for Kadmon Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kadmon Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply